Compare WABC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WABC | GLUE |
|---|---|---|
| Founded | 1972 | 2019 |
| Country | United States | United States |
| Employees | 627 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2021 |
| Metric | WABC | GLUE |
|---|---|---|
| Price | $58.75 | $11.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $64.00 | $28.50 |
| AVG Volume (30 Days) | 171.7K | ★ 949.3K |
| Earning Date | 10-15-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.40 | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $17.19 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $44.93 | $7.24 |
| 52 Week High | $63.61 | $25.77 |
| Indicator | WABC | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 28.92 |
| Support Level | $55.80 | N/A |
| Resistance Level | $60.49 | $15.00 |
| Average True Range (ATR) | 1.21 | 0.59 |
| MACD | -0.21 | 0.05 |
| Stochastic Oscillator | 0.00 | 9.06 |
Westamerica Bancorp provides a full range of banking services to individual and commercial customers in Northern and Central California through its subsidiary bank. The Bank is a California-chartered commercial bank whose deposits are insured by the Federal Deposit Insurance Corporation (the FDIC) up to applicable limits. The principal communities served are located in Northern and Central California, from Mendocino, Lake and Nevada Counties in the north to Kern County in the south. The Company's strategic focus is on the banking needs of small businesses.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).